PROgnostic Signature in stage II colon cancer (CC) patients enrolled in the phase III clinical trial TOSCA: PROSIT study

被引：0
|
作者：
Puccini, A. [1 ,2 ]
Ferrando, L. [3 ]
Mazzarella, L. [4 ]
Frige, G. [5 ]
Pessino, A. [6 ]
Pastorino, A. [7 ]
Martelli, V. [8 ]
Garuti, A. [2 ]
Ballestrero, A. [2 ]
Torri, V. [9 ]
Labianca, R. [10 ]
Fassan, M. [11 ]
Lonardi, S. [12 ]
Zoppoli, G. [13 ,14 ]
Sobrero, A. [15 ]
机构：
[1] IRCCS Humanitas Res Hosp, Humanitas Canc Ctr, Rozzano, Italy
[2] IRCCS Humanitas Res Hosp, Med Oncol & Hematol Unit, Rozzano, Italy
[3] IRCCS Osped Policlin San Martino, Dept Internal Med, Genoa, Italy
[4] IEO Ist Europeo Oncol IRCCS, New Drug Dev, Expt Oncol, Milan, Italy
[5] IEO Ist Europeo Oncol, Expt Oncol, Milan, Italy
[6] IRCCS Osped Policlin San Martino, Hematooncol Dept, Genoa, Italy
[7] IRCCS Osped Policlin San Martino, Dept Med Oncol, Genoa, Italy
[8] IRCCS Osped Policlin San Martino, Dipartimento Oncol Med 1, Genoa, Italy
[9] Ist Ric Farmacol Mario Negri IRCCS, Milan, Italy
[10] ASST Papa Giovanni XXIII, Prov Dept Oncol, Bergamo, Italy
[11] Azienda Univ Osped Padova, Padua, Italy
[12] IOV Ist Oncol Veneto IRCCS, Dept Oncol, Padua, Italy
[13] Univ Genoa, Dept Internal Med, Genoa, Italy
[14] Osped Policlin San Martino IRCCS DiMI, Genoa, Italy
[15] IRCCS Osped Policlin San Martino, Dept Med Oncol, Genoa, Italy
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.05.036
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
25P
引用
收藏
页码：S13 / S13
页数：1
相关论文
共 50 条
  • [21] Enhanced Clinical Utility of Molecular Budding Signature as a Recurrence Risk Determinant in Stage II and III Colon Cancer Patients
    Eiji Shinto
    Eiji Oki
    Mototsugu Shimokawa
    Shigeki Yamaguchi
    Megumi Ishiguro
    Seiji Hasegawa
    Yasumasa Takii
    Hideyuki Ishida
    Tetsuya Kusumoto
    Masaru Morita
    Naohiro Tomita
    Manabu Shiozawa
    Masafumi Tanaka
    Heita Ozawa
    Yojiro Hashiguchi
    Shinobu Ohnuma
    Sachiyo Tada
    Tomoko Matsushima
    Keisuke Yamagishi
    Kazuo Hase
    Annals of Surgical Oncology, 2023, 30 : 5239 - 5247
  • [22] Enhanced Clinical Utility of Molecular Budding Signature as a Recurrence Risk Determinant in Stage II and III Colon Cancer Patients
    Shinto, Eiji
    Oki, Eiji
    Shimokawa, Mototsugu
    Yamaguchi, Shigeki
    Ishiguro, Megumi
    Hasegawa, Seiji
    Takii, Yasumasa
    Ishida, Hideyuki
    Kusumoto, Tetsuya
    Morita, Masaru
    Tomita, Naohiro
    Shiozawa, Manabu
    Tanaka, Masafumi
    Ozawa, Heita
    Hashiguchi, Yojiro
    Ohnuma, Shinobu
    Tada, Sachiyo
    Matsushima, Tomoko
    Yamagishi, Keisuke
    Hase, Kazuo
    ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (08) : 5239 - 5247
  • [23] PROGNOSTIC FACTORS FOR PATIENTS WITH RECURRENT DISEASE IN STAGE II-III COLON CANCER
    Mateo, Joaquin
    Lopez-Doriga, Adriana
    Navarro, Matilde
    Martinez Villacampa, M. Mercedes
    Laquente, Berta
    Soler, Gemma
    Ramos, Emilio
    Biondo, Sebastiano
    Macia, Ivan
    Salazar, Ramon
    Santos, Cristina
    ANNALS OF ONCOLOGY, 2011, 22 : v107 - v107
  • [24] Phase III trial comparing 3-6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial
    Lonardi, S.
    Sobrero, A.
    Rosati, G.
    Di Bartolomeo, M.
    Ronzoni, M.
    Aprile, G.
    Scartozzi, M.
    Banzi, M.
    Zampino, M. G.
    Pasini, F.
    Marchetti, P.
    Cantore, M.
    Zaniboni, A.
    Rimassa, L.
    Ciuffreda, L.
    Ferrari, D.
    Barni, S.
    Zagonel, V.
    Maiello, E.
    Rulli, E.
    Labianca, R.
    ANNALS OF ONCOLOGY, 2016, 27 (11) : 2074 - 2081
  • [25] Clinical score to predict recurrence in patients with stage II and III colon cancer
    Vinal, D.
    Martinez-Recio, S.
    Martinez Perez, D.
    Jimenez-Bou, D.
    Ruiz, I.
    Pena, J.
    Martin-Montalvo, G.
    Alameda, M.
    Rueda-Lara, A.
    Gutierrez-Sainz, L.
    Palacios, M.
    Custodio, A.
    Ghanem, I.
    Feliu, J.
    Rodriguez-Salas, N.
    ANNALS OF ONCOLOGY, 2022, 33 : S279 - S279
  • [26] A robust circular RNA-based prognostic signature for postoperative recurrence in stage II/III colon cancer
    Ruan, Ji
    AIMS GENETICS, 2019, 6 (04): : 67 - 69
  • [27] The PARSC trial, a prospective study for the assessment of recurrence risk in stage II colon cancer (CC) patients using ColoPrint
    Salazar, R.
    Marshall, J.
    Stork-Sloots, L.
    Simon, I.
    Holzik, M. Lutke
    Tabernero, J.
    Van Der Hoeven, J. J.
    Bibeau, F.
    Rosenberg, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [28] The PARSC trial: A prospective study for the assessment of recurrence risk in stage II colon cancer (CC) patients using ColoPrint
    Salazar, R.
    Rosenberg, R.
    Holzik, M. Lutke
    Marshall, J.
    Van Der Hoeven, J. J.
    Glimelius, B.
    Bibeau, F.
    Stork-Sloots, L.
    Bender, R. A.
    Tabernero, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [29] Immunomonitoring in patients with stage II and III colon cancer
    Vocka, Michal
    Spacek, Jan
    Netikova, Irena
    Zavadova, Eva
    Nemejcova, Kristyna
    Konopasek, Bohuslav
    Dundr, Pavel
    Geppert, Carol-Immanuel
    Fucikova, Terezie
    Hartmann, Arndt
    Petruzelka, Lubos B.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [30] Prognostic Impact of Mucinous Adenocarcinoma in Stage II and III Colon Cancer
    Kim, Seijong
    Huh, Jung Wook
    Lee, Woo Yong
    Yun, Seong Hyeon
    Kim, Hee Cheol
    Cho, Yong Beom
    Park, Yoonah
    Shin, Jung Kyong
    DISEASES OF THE COLON & RECTUM, 2023, 66 (11) : 1473 - 1480
12345